Skip to content

Alzheimer s & Dementia

ISSN 1552-5260, 1552-5279

11 papers in the library · 28 citations · publishing 2011-2025

Papers

Sort Most recent Most cited

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study

Alzheimer s & Dementia December 1, 2025 Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.

Abstract Background Amnestic mild cognitive impairment (aMCI) is characterized by synaptic loss and cognitive decline and is considered a precursor to Alzheimer’s Disease. Currently, there are no effective treatments for aMCI, and available treatments (i.e., cholinesterase inhibitors) do not appear to improve cognitive or functional outcomes. Psychedelics, including psilocybin, have regained...

DOI: 10.1002/alz70859_101101 (opens in new tab) Psilocybin Tolerability Memantine Adverse effect +11

Dream recall in cognitively healthy older adults: associations with blood p ‐tau217 levels, APOE ε4 carriage, and cognitive decline

Alzheimer s & Dementia December 1, 2025 Darren M. Lipnicki, Meritxell Valenti, Elizabeth Lucia Valeriano‐Lorenzo et al.

Abstract Background Evidence suggests that dreaming is subserved by the default mode network (DMN) (Domhoff, 2022. The Neurocognitive Theory of Dreaming ). β‐amyloid plaques and phosphorylated tau ( p ‐tau) protein tangles accumulate and contribute to abnormal functionality in the DMN long before clinical Alzheimer's disease, and similarly early abnormal DMN functionality is shown by...

DOI: 10.1002/alz70857_097922 (opens in new tab) Cognitive decline Recall Dream Dementia +6

Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis

Alzheimer s & Dementia December 1, 2025 Leelavathi N. Madhu, Yogish Somayaji, Sanya Kotian et al.

Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognitive and mood function. Currently, there are no effective therapies to alleviate the progression of brain dysfunction in AD. Psilocybin, an FDA‐approved drug for treating major depressive disorder, can restrain neuroinflammation and improve...

Magic mushrooms‐ P. cubensis and H. erinaceus a possible novel treatment for Alzheimer's disease symptoms

Alzheimer s & Dementia December 1, 2025 Anjali Rose Friedman

Abstract Background Recent studies have highlighted the neuroprotective properties of certain mushrooms. Proposing a research hypothesis for a novel field of study into mitigating the neurological and neuropsychological symptoms associated with Alzheimer's disease (AD) and possible cure with natural methods. Psilocybe cubensis and Hericium erinaceus have proven to show therapeutic effects for...

DOI: 10.1002/alz70856_097076 (opens in new tab) Disease Magic telescope Realm Context archaeology

Exploring Therapeutic Potentials and Pathways of Psychedelics in Alzheimer’s Disease‐Related Dementia

Alzheimer s & Dementia December 1, 2024 Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh et al. 1 citation

Abstract Background Traditionally associated with recreational and spiritual uses, psychedelics have gained attention in psychotherapy for their therapeutic potential. Functioning as potent 5‐hydroxytryptamine (5HT) agonists, these compounds have demonstrated the ability to enhance neural plasticity by activating serotoninergic and glutamatergic systems. Despite these recognized effects, their...

DOI: 10.1002/alz.084413 (opens in new tab) Dementia Alzheimer's disease Pathology

Effect of increasing cognitive activity participation on functional connectivities within default mode network– a randomized controlled trial

Alzheimer s & Dementia December 1, 2024 Allen TC Lee

AbstractBackgroundWe previously reported that increasing participation in Chinese calligraphy handwriting, one of the “Four Arts” traditionally mastered by intellectuals in China and currently widely practiced by older adults in the Chinese community, led to better working memory among individuals with subjective cognitive decline (but without mild or major neurocognitive disorder). Given that...

Unexpected awakenings in severe dementia from case reports to laboratory.

Alzheimer s & Dementia 2021 Mehmet Bostancıklıoğlu 17 citations

Case report notions of unexpected memory retrieval in patients with severe dementia near to death are starting to alter the central "irreversible" paradigm of dementia and locate dementia as a problem of memory retrieval, not consolidation. We suggest that the most likely central tenet of this paradoxical memory retrieval is the fluctuation of neuromodulators projecting from the brain stem to...

The effect of mindfulness‐based programs on cognitive performance across the lifespan: A systematic review and meta‐analysis

Alzheimer s & Dementia December 1, 2020 Tim Whitfield, Thorsten Barnhofer, Rebecca L. Acabchuk et al. 6 citations

Abstract Background The primary focus of mindfulness‐based program (MBP) research to date has been on mental health. More recently, attention has turned to putative effects on cognition. An evidence synthesis is required to answer the key question of ‘Do MBPs confer cognitive benefit, and if so, for whom?’ A particularly crucial distinction is whether benefits differ according to individuals’...

DOI: 10.1002/alz.043562 (opens in new tab) Mindfulness Meta-analysis Cognition Systematic review +6

Microdosing of scopolamine as a “cognitive stress test”: Rationale and test of a very low dose in an at‐risk cohort of older adults

Alzheimer s & Dementia March 1, 2014 Peter J. Snyder, Yen Ying Lim, Rachel Schindler et al.

Abstract: Background: Abnormal β‐amyloid (Aβ) is associated with deleterious changes in central acetylcholinergic tone in the very early stages of Alzheimer's disease (AD), which may be unmasked by a cholinergic antagonist. We aimed to establish an optimal “microdose” of scopolamine for the development of a “cognitive stress test.” Methods: Healthy older adults (n = 26, aged 55–75 years) with...

P2‐370: Mindfulness‐based stress reduction for caregivers of patients with Alzheimer's disease

Alzheimer s & Dementia July 1, 2011 Lap Ho, Patricia A. Bloom, Joan Griffiths Vega et al. 4 citations

Numerous studies have documented that caregiving for a dementia patient may be associated with increased risk of emotional distress, depression, dementia, physical health problems, and death. Other studies suggest that targeting caregivers as the recipients of interventions may greatly improve Alzheimer's care, leading to reduced behavioral symptoms and increased length of time that the...

IC‐P‐112: Altered intrinsic functional connectivity of default mode network in a patient with posterior cortical dysfunction syndrome

Alzheimer s & Dementia July 1, 2011 Márcio Luiz Figueredo Balthazar, Tátila Martins Lopes, Ana Carolina Coan et al.

Dysfunction of brain's Default Mode Network (DMN) has been increasingly described in patients with neurodegenerative diseases, but little is known about DMN's intrinsic functional connectivity (IFC) in Posterior Cortical Dysfunction (PCD) syndrome. We report a 56 year-old woman with PCD syndrome (MMSE = 24, CDR = 0.5) with visuospatial and anxiety complaints, confirmed by neuropsychological...